Cellectis Q2 Adj $(0.15) Beats $(0.45) Estimate, Sales $2.00M Miss $4.48M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cellectis reported Q2 losses of $(0.15) per share, beating the analyst consensus estimate of $(0.45) by 66.67%. However, the company's quarterly sales of $2.00 million missed the analyst consensus estimate of $4.48 million by 55.31%. This represents a 27.59% decrease over sales of $2.77 million the same period last year.
August 07, 2023 | 9:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cellectis reported better than expected Q2 earnings but missed on sales.
While the company beat earnings estimates, the miss on sales could offset any potential positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100